Mixed results with positive revenue growth (8.8%), improved margins (51% vs 43%), and strong data-license revenue growth (187.1%), but offset by stock decline post-earnings (-1.8%), elevated operating expenses, negative operating cash flow, and cautious management guidance with no formal revenue/earnings outlook provided. The company's strategic pivot away from flow cytometry and ongoing search for external funding suggest uncertainty.
Mixed results with strong operational metrics (record study revenue +32% YoY, third consecutive quarter of positive adjusted EBITDA) offset by near-term headwinds (overall revenue decline -3%, significant gross margin compression to 47%, negative operating cash flow of $1.4M). Management maintains full-year guidance for revenue growth and positive EBITDA, with early data business momentum providing some optimism, but execution risks remain around margin recovery and external funding for Corellia subsidiary.
Articles that tag CSBR but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
